0
Business
Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients
April 27, 2026
Scroll
Posted 2 hours ago by
Compass Therapeutics says tovecimig misses overall survival endpoint in biliary tract cancer study, but data shows progression-free survival and response rates. Latest Ratings for CMPX DateFirmActionFromTo Jan 2022B. Riley SecuritiesInitiates Coverage OnBuy Dec 2021Raymond JamesInitiates Coverage OnOutperform Dec 2021SVB LeerinkInitiates Coverage OnOutperform View More Analyst Ratings for CMPX View the Latest Analyst Ratings Importance Rank: 2 read more
Benzinga
Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.
United States of America
Bias: center
People's Voices (0)
Leave a comment
0/500
Note: Comments are moderated. Please keep it civil. Max 3 comments per day.